Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival
Year: 2025
Type: article
Abstract: BACKGROUND: Gastric cancer (GC) is a significant cancer-related cause of death worldwide. GC's most used chemotherapeutic regimen is based on platinum drugs such as cisplatin (CDDP). However, CDDP chemoresistance reduces the survival rate of advanced GC. The immune C-C chemokine receptor type 5 (CCR5) have been proposed as a pivotal factor in cancer progression since its blockade has been linked with antineoplastic effects on tumor cell proliferation; nevertheless, its role in the chemoresistance of GC has not been elucidated. This study aimed to determine the effects induced by the CCR5 using Maraviroc (MVC), a highly selective CCR5 antagonist, on CDDP-resistant AGS cells (AGS R-CDDP), tumoroids (3D tumor spheroids), and animal models. RESULTS: The combined CDDP and MVC treatment reduced cell viability and inhibited tumoroid formation in AGS R-CDDP cells. The effects of the MVC/CDDP combination on apoptosis and cell cycle progression were correlated with the increase in CDDP (dose-dependent). The mRNA levels of C-C Motif Chemokine Ligand 5 (CCL5), the main ligand for CCR5, decreased significantly in cells treated with the MVC/CDDP combination. MVC in the MVC/CDDP combination improved the survival rate and biochemical parameters of CDDP-treated mice by reducing the side effects of CDDP alone. CONCLUSIONS: This finding suggests that MVC/CDDP combination could be a potential complementary therapy for GC.
Source: Biological Research
Authors: Bárbara Mora-Lagos, María Elena Reyes, Lorena Lobos-Gonzalez, Matías del Campo, Kurt Buchegger, Louise Zanella, Ismael Riquelme, Carmen Gloria Ili, Priscilla Brebi
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,790
Funders: Institut Català de Nanociència i Nanotecnologia, Universidad de La Frontera, Instituto Milenio en Inmunología e Inmunoterapia, Biomedical Research Consortium-Chile, Agencia Nacional de Investigación y Desarrollo, Fondo Nacional de Desarrollo Científico y Tecnológico, Fondo de Fomento al Desarrollo Científico y Tecnológico, Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias
Awards: G1429601193, G1722883863, G2007556644, G2471211615, EXPLORING THE UNCHARACTERIZED PAN-TRANSCRIPTOME ASSOCIATED WITH GASTRIC CANCER IN CHILE, G3556820384, LACTADHERIN IN EXOSOMES SECRETED BY BREAST CANCER CELLS INTERACTS WITH α- Vβ- 3 INTEGRIN IN EPITHELIAL CANCER CELLS AND IN ENDOTHELIAL CELLS LEADING TO EPITHELIAL-MESENCHYMAL TRANSITION INCREASED VASCULAR PERMEABILITY AND METASTASIS POST-SURGERY, NUEVA FORMULACION FOTOSENSIBILIZADORA EN TERAPIA FOTODINAMICA PARA EL TRATAMIENTO DE CANCER DE PIEL NO MELANOMA, G4606729794, G6481653303, G652983587, ROLE OF THE CHEMOKINE RECEPTORS CCR3 AND CXCR2 IN CHEMORESISTANT GASTRIC CANCER A POTENTIAL COADJUVANT THERAPY IN TREATMENTS BASED ON CISPLATIN AND 5-FLUOROURACIL DRUGS, G7007120338, MILLENNIUM INSTITUTE ON IMMUNOLOGY AND IMMUNOTHERAPY, G7765489441, CENTRO DE ESTUDIOS AVANZADOS DE ENFERMEDADES CRONICAS (ACCDIS), G8591489707, "THE ROLE OF SPECIFIC LONG NON-CODING RNAS (LNCRNAS) AS REGULATORS OF THE PI3K/AKT/MTOR PATHWAY IN CHEMORESISTANT GASTRIC CANCER A POTENTIAL STRATEGY TO ENHANCE THE RESPONSE TO CISPLATIN AND/OR 5-FLUOROURACIL DRUGS., G99091514
OpenAlex ID: W4406512358